Form 6K CASI Pharmaceuticals For: 2 June
- Investing.com
- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
CASI Pharmaceuticals Inc (CASIF)
The Casi Pharma share price today is 0.1660, view OTC CASIF stock exchange data. Track the latest Casi Pharma share price with real-time updates on CASIF stock performance including market cap, day range, 52-week range and dividend yield. Access CASIF charts, earnings dates and analyst estimates to support your investment decisions.
0.1660
+0.0127(+8.29%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.1660
0.1660
52 wk Range
0.0500
3.0900
CASIF is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.16600.1660
52 wk Range
0.05003.0900
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
CASIF Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceAnalysts Sentiment
Strong Buy
Price Target
4.0000
Upside
+2,309.64%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
May have trouble making interest payments on debt
- Form 13D/A CASI Pharmaceuticals For: 18 May
- Investing.com
- Form 6K CASI Pharmaceuticals For: 3 March
- Investing.com
- Form 6K CASI Pharmaceuticals For: 20 April
- Investing.com
- Form 6K CASI Pharmaceuticals For: 2 June
- Investing.com
- Form 13D/A CASI Pharmaceuticals For: 18 May
- Investing.com
- Form 6K CASI Pharmaceuticals For: 20 April
- Investing.com
- Form 6K CASI Pharmaceuticals For: 15 April
- Investing.com
- Form 13D/A CASI Pharmaceuticals For: 23 March
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Analyst Ratings
1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 4.0000
(+2,309.64% Upside)
Earnings
Latest Release
15-05-2026
EPS / Forecast
-0.48 / -0.28
Revenue / Forecast
7.22M / --
Compare CASIF to Peers and Sector
Metrics to compare | CASIF | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCASIFPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.1x | −4.5x | −0.4x | |
PEG Ratio | 0.06 | −0.05 | 0.00 | |
Price/Book | −0.1x | 1.4x | 2.6x | |
Price / LTM Sales | 0.2x | 63.3x | 3.0x | |
Upside (Analyst Target) | - | 179.0% | 53.5% | |
Fair Value Upside | Unlock | 3.7% | 9.0% | Unlock |
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People’s Republic of China, the United States, and internationally. It offers EVOMELA, a Melphalan injection for use as a conditioning treatment prior to stem cell transplantation and as a palliative treatment for patients with multiple myeloma. The company also develops CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with hematological malignancies; BI-1206, an novel anti-Fc?RIIB antibody for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody for the treatment of patients with multiple myeloma; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. It has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People’s Republic of China.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Casi Pharma (CASIF) Share Price Today?
The Casi Pharma share price today is 0.1660.
What is the current Casi Pharma (CASIF) share price and day range?
As of 19-07-2026, the Casi Pharma share price is 0.1660, with a previous close of 0.1533. The share price has ranged from 0.1660 to 0.1660 today, while the 52-week range spans from 0.0500 to 3.0900.
What Is the Casi Pharma Market Cap?
As of today, Casi Pharma market cap is 3.4100M.
What Is the Casi Pharma (CASIF) Share Price Target?
The average 12-month share price target for Casi Pharma is 4.0000, with a high estimate of 4 and a low estimate of 4. 1 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +2,309.64% Upside potential.
What Is Casi Pharma's Earnings Per Share (TTM)?
The Casi Pharma EPS (TTM) is -2.5924.
From a Technical Analysis Perspective, Is CASIF a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.
What Stock Exchange Does Casi Pharma Trade On?
Casi Pharma is listed and trades on the OTC Markets.
What Is the Stock Symbol for Casi Pharma?
The stock symbol for Casi Pharma is "CASIF."
How Many Times Has Casi Pharma Stock Split?
Casi Pharma has split 2 times.
How Many Employees Does Casi Pharma Have?
Casi Pharma has 214 employees.
What Is the CASIF After Hours Price?
CASIF's last after hours stock price is 0.2028, the stock has changed by 0.0028, or 1.4000%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.